Amneal Pharmaceuticals (NYSE: AMRX) reported Q2 EPS of $0.24, $0.02 better than the analyst estimate of $0.22. Revenue for the quarter came in at $462.33 million versus the consensus estimate of $460.81 million.

GUIDANCE:

Revised full year 2018 adjusted EBITDA and adjusted EPS guidance primarily due to the delayed timing of deliveries of Epinephrine Auto-Injector. Amneal Pharmaceuticals sees FY2018 EPS of $0.90-$1.00, versus prior of $0.95-$1.10 and the consensus of $1.02.

For earnings history and earnings-related data on Amneal Pharmaceuticals (AMRX) click here.